Analysts predict that Crispr Therapeutics AG (NASDAQ:CRSP) will post earnings of ($0.92) per share for the current quarter, Zacks Investment Research reports. Two analysts have provided estimates for Crispr Therapeutics’ earnings. The highest EPS estimate is ($0.73) and the lowest is ($1.01). Crispr Therapeutics posted earnings per share of ($0.82) during the same quarter last year, which would indicate a negative year over year growth rate of 12.2%. The company is expected to announce its next earnings results on Tuesday, August 6th.
On average, analysts expect that Crispr Therapeutics will report full year earnings of ($3.82) per share for the current fiscal year, with EPS estimates ranging from ($4.18) to ($3.17). For the next financial year, analysts anticipate that the firm will post earnings of ($4.26) per share, with EPS estimates ranging from ($5.04) to ($3.24). Zacks’ EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for Crispr Therapeutics.
Crispr Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings results on Monday, April 29th. The company reported ($0.93) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.90) by ($0.03). The company had revenue of $0.30 million during the quarter, compared to the consensus estimate of $1.50 million. Crispr Therapeutics had a negative net margin of 8,839.02% and a negative return on equity of 50.90%. The company’s quarterly revenue was down 78.6% on a year-over-year basis. During the same quarter last year, the firm posted ($0.62) earnings per share.
In other Crispr Therapeutics news, CEO Samarth Kulkarni sold 20,000 shares of the company’s stock in a transaction on Monday, April 29th. The stock was sold at an average price of $42.03, for a total transaction of $840,600.00. Following the completion of the sale, the chief executive officer now directly owns 186,542 shares in the company, valued at $7,840,360.26. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 37.70% of the stock is owned by corporate insiders.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Bank of New York Mellon Corp lifted its holdings in Crispr Therapeutics by 11.3% in the third quarter. Bank of New York Mellon Corp now owns 34,618 shares of the company’s stock valued at $1,535,000 after acquiring an additional 3,514 shares during the period. Morgan Stanley lifted its holdings in Crispr Therapeutics by 18.4% in the third quarter. Morgan Stanley now owns 232,540 shares of the company’s stock valued at $10,313,000 after acquiring an additional 36,098 shares during the period. Vanguard Group Inc. lifted its holdings in Crispr Therapeutics by 6.6% in the third quarter. Vanguard Group Inc. now owns 52,023 shares of the company’s stock valued at $2,307,000 after acquiring an additional 3,200 shares during the period. Vanguard Group Inc lifted its holdings in Crispr Therapeutics by 6.6% in the third quarter. Vanguard Group Inc now owns 52,023 shares of the company’s stock valued at $2,307,000 after acquiring an additional 3,200 shares during the period. Finally, Strs Ohio acquired a new stake in Crispr Therapeutics in the fourth quarter valued at $925,000. Hedge funds and other institutional investors own 48.96% of the company’s stock.
Shares of CRSP stock traded up $5.63 during trading on Friday, hitting $42.88. The company had a trading volume of 1,865,810 shares, compared to its average volume of 341,146. The company has a current ratio of 15.84, a quick ratio of 15.84 and a debt-to-equity ratio of 0.08. The stock has a market cap of $2.27 billion, a P/E ratio of -12.47 and a beta of 2.96. Crispr Therapeutics has a one year low of $22.22 and a one year high of $70.09.
About Crispr Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.